A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.
A Prospective, Randomized, Double-blind, Parallel-group, Sham Controlled Single-center Pivotal Clinical Investigation to Evaluate the Clinical Safety and Performance of Self-administered Home-use Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation Device (Relievion™) in Treating Migraine.
Sponsor: Neurolief Ltd.
Terminated
Investigator retierment
This NA trial investigates Migraine and is currently terminated or withdrawn. Neurolief Ltd. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Apr 2018 — Jun 2018 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
▶ Show 2 earlier versions
-
Jan 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Not Yet Recruiting → Active Not Recruiting
-
Jul 2017 — Jan 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Neurolief Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .